spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

New research calls for pathology services to be better funded and prioritised

MindMetre Research

Research report from MindMetre presents evidence of the high value offered by pathology services, and suggests that current efficiency savings plans be reviewed

A new report from independent research organisation MindMetre has summarised the evidence for return-on-investment from pathology services in the NHS and questioned any urgent pressure to consolidate pathology laboratories - within and between NHS trusts.

The MindMetre report, which reviewed the range of existing evidence and also canvassed views among a sample of 30 laboratory managers and principal biochemists in England and Wales, was conducted in response Lord Carter’s latest report, Operational productivity and performance in English NHS acute hospitals: Unwarranted variations (February 2016).

The Carter report notes that, “If benchmarks for pathology are unlikely to be achieved [by the deadline of April 2017], trusts should have agreed plans for consolidation and outsourcing to, other providers by January 2017.” The MindMetre review and research cautions against such a tight deadline being imposed, arguing that merger planning is not a substitute for within-laboratory efficiency and improvement drives.

The MindMetre review suggests that a mandatory pathway is set for laboratory productivity improvement (particularly turnaround time reduction), recognising that all aspects of the NHS have to deliver efficiency savings in the current policy environment. However, the review also suggests that the high value offered by pathology services be re-appraised at the strategic level to determine their position in the NHS service funding priorities.

Evidence covered in the review suggests that the immediate and knock-on effects of pathology service capacity and efficiency/productivity are more considerable than service funding would suggest, and could make an even more disproportionately positive contribution to patient outcomes, rapid diagnosis and the avoidance of unnecessary interventions and chronic condition development further down the line.

Paul Lindsell, Mind Metre Managing Director, comments: “A knee-jerk push to consolidate pathology labs is not an easy universal panacea. There is evidently significant headroom for efficiency and productivity gains in pathology workflows and emerging technology. Our report recognises frustrations that greater productivity gains have not yet been achieved. However, we also suggest that the through-the-line benefits that pathology services offer mean it would be a mistake to potentially squeeze such resources in the NHS. In fact, there may be a rationale to put greater resources into pathology services, so long as they are strictly pegged to productivity improvements.”
email info@mindmetre.com
web www.mindmetreresearch.com/
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound


More info >>


White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement